Being tested
Fumarates / NRF2: reduce relapses and new lesions in relapsing MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
relapsing MS · Fumarates / NRF2
Trials are running now and no controlled trial has a readable result yet.
1 trial(s) stopped for safety reasons.
- Trials
- 15
- Running now
- 2
- Controlled phase 2/3 trials
- 6
- People in controlled trials
- 3072
Deciding trials (phase 3): 3 met, 0 did not.
Other linked trials: 12
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2026 · Placebo-controlled · MSFT-NCT07483632
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participantsdecides the statusStopped: safety
Phase 3 · 2019 · Placebo-controlled · MSFT-NCT03870763
Phase 3 · 2016 · Placebo-controlled · MSFT-NCT02428218
- An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)decides the statusMet main goal
Phase 3 · 2013 · Placebo-controlled · MSFT-NCT01838668
From weeks 12 - 24, the total number of new gadolinium-enhancing (Gd + ) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo.
Read by software from the paper's abstract Phase 3 · 2007 · Compared with glatiramer acetate · MSFT-NCT00451451
At 2 years, the annualized relapse rate was significantly lower with twice-daily BG-12 (0.22), thrice-daily BG-12 (0.20), and glatiramer acetate (0.29) than with placebo (0.40) (relative reductions: twice-daily BG-12, 44%, P<0.001; thrice-daily BG-12, 51%, P<0.001; glatiramer acetate, 29%, P=0.01).
Read by software from the paper's abstractPhase 3 · 2007 · Placebo-controlled · MSFT-NCT00420212
The estimated proportion of patients who had a relapse was significantly lower in the two BG-12 groups than in the placebo group (27% with BG-12 twice daily and 26% with BG-12 thrice daily vs. 46% with placebo, P<0.001 for both comparisons).
Read by software from the paper's abstract
Other linked trials: 12
These linked trials do not set the status.
- A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaNo result found
Phase 4 · 2023 · Not randomised
- PROMPTStopped, other reason
Phase 4 · 2015 · Placebo-controlled
- PROMPTStopped, other reason
Phase 4 · 2015 · Placebo-controlled
- PROTECResult in a paper, not read yet
Phase 4 · 2013 · Not randomised
- TWINSOngoing
Phase 3 · 2025 · Not randomised
- CONNECTNo result found
Phase 3 · 2014 · Compared with interferon beta-1a
- FOCUSMet main goal
Phase 2 · 2015 · Not randomised
- Efficacy and Safety of BG00012 in MSMet main goal
Phase 2 · 2004 · Not randomised
- TREAT-MSResult in a paper, not read yet
Phase not applicable · 2018 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 17 → 15
- 2026-10-27First listed as Being tested
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error